Hypertriglyceridemia is an elevation of blood triglyceride levels that can increase risk of atherosclerotic cardiovascular disease and, at very high levels, acute pancreatitis.
Updated pediatric hypertriglyceridemia guidance says triglyceride thresholds below 400 mg/dL mainly signal ASCVD risk, while levels above about 885 mg/dL raise pancreatitis risk. Lifestyle changes remain first-line treatment, and pediatric-specific evidence for drug therapy is still limited.
Arrowhead Pharmaceuticals presented long-term data showing plozasiran achieved 83% median triglyceride reduction in severe hypertriglyceridemia patients with no acute pancreatitis events over two years. The RNA interference therapy demonstrated durable improvements in atherogenic lipoproteins and consistent safety profile. The company plans to complete Phase 3 studies by mid-2026 and submit for regulatory approval.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07604974 |
A Study to Assess the Safety, Tolerability and Efficacy of ION775 |
RECRUITING | PHASE2 |
| NCT07587788 |
RBD5044 in Chinese Participants With Hypertriglyceridemia |
RECRUITING | PHASE2 |
| NCT07491172 |
A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias |
RECRUITING | PHASE1 |
| NCT07406191 |
WB-EMS Effects on Cardiometabolic Risk Factors |
ACTIVE_NOT_RECRUITING | NA |
| NCT07028749 |
Study of MAR001 in Adults With Elevated Triglycerides and Remnant Cholesterol |
ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT07004777 |
Effect of Consuming n-3 Polyunsaturated Fatty Acids Rich Foods on Triglyceride Concentration and Lipoprotein Composition |
RECRUITING | NA |
| NCT06822790 |
Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia |
RECRUITING | PHASE3 |
| NCT06451770 |
Phase 1b Study of VERVE-201 in Patients With Refractory Hyperlipidemia |
RECRUITING | PHASE1 |
| NCT05355402 |
A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Adults With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease (Established or at Increased Risk for), and/or With Severe Hypertriglyceridemia |
COMPLETED | PHASE2 |
